| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Esophageal Cancer | |||||
| Gastric Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Adenocarcinoma | |||||
| Esophageal Diseases | |||||
| Esophageal Neoplasms | |||||
| Stomach Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Carcinoma | |||||
| Digestive System Diseases | |||||
| Digestive System Neoplasms | |||||
| Gastrointestinal Diseases | |||||
| Gastrointestinal Neoplasms | |||||
| Head and Neck Neoplasms | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Stomach Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| irinotecan hydrochloride | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Camptothecin | |||||
| Irinotecan | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Phytogenic | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| North Central Cancer Treatment Group | |||||
| National Cancer Institute (NCI) | |||||
|
